Evidence map›Paper›PMID 35602829›Full record

ArticleCureus2022

Male Breast Metastasis: A Case of Treatment-Emergent Neuroendocrine Prostate Cancer.

Rita Sismeiro, Margarida Brito Monteiro, Catarina Negrão, Tiago Tomás, Marta Jonet

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Rita SismeiroInternal Medicine, Hospital Prof. Doutor Fernando Fonseca, Amadora, PRT.
Margarida Brito MonteiroInternal Medicine, Hospital Prof. Doutor Fernando Fonseca, Amadora, PRT.
Catarina NegrãoInternal Medicine, Hospital Prof. Doutor Fernando Fonseca, Amadora, PRT.
Tiago TomásOncology, Hospital Prof. Doutor Fernando Fonseca, Amadora, PRT.
Marta JonetInternal Medicine, Hospital Prof. Doutor Fernando Fonseca, Amadora, PRT.
Hospital Prof. Dr. Fernando Fonseca · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment-emergent transformed neuroendocrine prostate cancer (NEPC) is a highly aggressive type of prostate cancer that may arise from typical adenocarcinoma of the prostate, which is associated with rapidly progressive disease involving visceral sites and refractoriness to hormonal therapy. We present the case of a 74-year old male with a known history of stable prostate adenocarcinoma treated with transurethral prostate resection, local radiotherapy (RT), and androgen deprivation therapy (ADT) in 2020 who presented to the emergency room with complaints of shoulder and anterior chest pain, dyspnoea, and fatigue. Upon examination, a solid, adherent breast mass and infra-clavicular adenopathy were palpable. Thoracic computed tomography (CT) scan showed adenopathies in multiple thoracic chains, bilateral pulmonary nodular opacities, multiple osteolytic lesions, and bilateral enlargement of retro areolar tissue. A staging CT scan revealed further hepatic and penile lesions. Breast mass biopsy was compatible with small cell neuroendocrine cancer. Biopsies of the prostate, penis, lymph nodes, and bronchus were also performed. Histology of the prostate showed focal infiltration by the known adenocarcinoma while all others documented extensive infiltration by neuroendocrine carcinoma, whose morphology and immunohistochemical profile were identical to that of the breast. This case highlights the challenges a diagnosis of neuroendocrine prostate cancer might pose, and the aggressiveness of this type of cancer, which frequently presents with advanced disease and is associated with poor outcomes.

Indexed as

breast metastasiscastration resistant metastatic prostate cancerlung metastasismale breast cancerspenile metastasissmall cell carcinoma of the prostatetreatment emergent neuroendocrine prostate cancer

Identifiers

PMID35602829
PMCPMC9119567
OpenAlexW4224299381

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.